gefitinib has been researched along with calpain in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (calpain) | Trials (calpain) | Recent Studies (post-2010) (calpain) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 7,019 | 25 | 2,422 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, C; Chang, M; Fang, T; Hong, Q; Li, J; Zhang, G; Zhou, J | 1 |
1 other study(ies) available for gefitinib and calpain
| Article | Year |
|---|---|
Calpain 2 knockdown promotes cell apoptosis and restores gefitinib sensitivity through epidermal growth factor receptor/protein kinase B/survivin signaling.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Calpain; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Survivin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |